Macrolide Resistance Found in Many M. genitalium Cases

New study reveals that over 40 percent of U.S. Mycoplasma genitalium infections carry macrolide resistance mutations.

Updated on Oct. 21, 2026 in Sex Life

A close-up of a laboratory pipette and a rack of glass test tubes on a sterile stainless steel surface. — A recent study found that 42.7 percent of U.S. Mycoplasma genitalium infections carry macrolide resistance mutations, complicating treatment for millions of patients. AI Illustration. Upload story photo >

Live Poll

Is the current healthcare system sufficiently prepared to manage the rise of antibiotic-resistant infections?

Data from the 2017-2018 National Health and Nutrition Examination Survey shows that 42.7 percent of U.S. Mycoplasma genitalium infections exhibit macrolide resistance. This prevalence affects an estimated 1.4 million people, with the A2058G mutation identified as the most common genetic marker.

Why it matters

The high prevalence of resistance is likely a consequence of widespread antibiotic use, which complicates the effective treatment of these common infections. Researchers note that resistance rates are significantly higher among younger populations, highlighting a key demographic challenge in reproductive health.

Researchers found that macrolide resistance mutation prevalence was 64.3 percent in those under 25 and 30.7 percent in those 25 or older. Overall, these mutations represent roughly 1.4 million infections in the United States.

The details

Using reverse transcriptase polymerase chain reaction and PyroMark24 sequencing, scientists analyzed urine specimens to map resistance profiles. While macrolide resistance was pervasive, the study found no quinolone resistance-associated mutations in the tested parC or gyrA genes.

2017-2018: Data collection period for the national health survey.
October 9, 2026: Study publication date.

Culture Shift

This study underscores a growing trend toward antibiotic resistance driven by the historical use of macrolides in clinical settings. It marks a critical pivot in public health surveillance as medical experts adjust strategies to combat increasingly resilient pathogens.

Patients may find that standard antibiotic treatments are becoming less effective due to these genetic mutations in the bacteria. This trend underscores the importance of consulting with healthcare providers regarding specific testing and treatment options for recurring infections.

The takeaway

The high mutation rates serve as a reminder that routine antibiotics may not always be the most effective choice for every infection. Patients are encouraged to discuss antibiotic resistance with their doctors to ensure the best possible treatment plan for their needs.